相关实验视频

Updated: May 27, 2025

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

勒伯遗传性视神经病 - - 伊德本和基因替代疗法的现状

Thomas Klopstock¹, Leopold H Zeng¹, Claudia Priglinger²

¹LMU Munich Friedrich Baur Institute at the Department of Neurology, LMU University Hospital Ziemssenstr. 1 80336 Munich Germany.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V

|February 18, 2025

概括

勒伯遗传性视神经病 (LHON) 是一种常见的线粒体疾病. 像idebenone和基因疗法这样的治疗方法为患有这种视神经疾病的患者恢复视力提供了希望.

科学领域:

遗传学遗传学是一个
神经学神经学
眼科医生眼科眼科

背景情况:

勒伯遗传性视神经病 (LHON) 是最常见的线粒体疾病,历史上与线粒体DNA (mtDNA) 变异有关.
最近已经确定了LHON的自体递归形式,扩大了这种疾病的已知的遗传基础.
临床上,LHON呈现为亚急性,无痛的中央视力敏度丧失,通常最初影响一只眼睛,其次是第二只眼睛.

研究的目的:

总结Leber遗传性视神经病变的遗传基础,临床表现和当前/新兴的治疗策略.
要突出复合I功能障碍在LHON病变发生中的作用.
讨论抗氧化剂和基因疗法在LHON治疗中的潜力.

主要方法:

对LHON遗传学,病理生理学和临床试验的现有文献的审查.
分析作为治疗剂的idebenone的作用机制.
对LHON的基因替代和基因编辑正在进行的研究的概述.

主要成果:

LHON主要是由影响呼吸链复合体I的核基因的致病变体引起的.
复杂I功能障碍导致ATP合成减少,反应性氧物种增加和视网膜质细胞亡.
抗氧化剂Idebenone可以绕过复合I缺乏症,并已被批准用于欧盟的LHON治疗.
内基因替代疗法正在临床试验的后期阶段,基因编辑作为未来的选择.

结论:

LHON的发病包括线粒体功能障碍,特别是复杂I缺陷,导致视神经退化.
目前的治疗方法,如idebenone通过减轻氧化应激和支持线粒体功能提供治疗途径.
先进的疗法,包括基因替代和基因编辑,对未来的LHON管理具有重大前景.

关键词:

综合体I 是一个综合体.伦敦LHON 在线观看基因治疗的基因疗法这是一种idebenone.我们的mtDNA mtDNA

更多相关视频

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye

Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye

Published on: November 25, 2012

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.